GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Equity-to-Asset

Alphamab Oncology (HKSE:09966) Equity-to-Asset : 0.76 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alphamab Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$1,753.4 Mil. Alphamab Oncology's Total Assets for the quarter that ended in Jun. 2024 was HK$2,306.0 Mil. Therefore, Alphamab Oncology's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.76.

The historical rank and industry rank for Alphamab Oncology's Equity-to-Asset or its related term are showing as below:

HKSE:09966' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32   Med: 0.76   Max: 0.87
Current: 0.76

During the past 7 years, the highest Equity to Asset Ratio of Alphamab Oncology was 0.87. The lowest was -0.32. And the median was 0.76.

HKSE:09966's Equity-to-Asset is ranked better than
61.24% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:09966: 0.76

Alphamab Oncology Equity-to-Asset Historical Data

The historical data trend for Alphamab Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Equity-to-Asset Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.85 0.86 0.69 0.74 0.78

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.74 0.79 0.78 0.76

Competitive Comparison of Alphamab Oncology's Equity-to-Asset

For the Biotechnology subindustry, Alphamab Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphamab Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Equity-to-Asset falls into.



Alphamab Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Alphamab Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1828.921/2337.529
=0.78

Alphamab Oncology's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=1753.421/2305.958
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alphamab Oncology  (HKSE:09966) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Alphamab Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.
Executives
South Dakota Trust Company Llc 2301 Trustee
Xu Ting 2305 Beneficiary of a trust
Liu Yang 2307 Founder of a discretionary trust who can infl
Rubymab Ltd. 2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines